Finasteride

Type II 5α-Reductase Inhibition#

Finasteride is a competitive, mechanism-based ("suicide") inhibitor of 5α-reductase type II, the isoenzyme concentrated in scalp dermal papilla, prostate, epididymis, and genital skin. It binds the enzyme's active site and forms a stable NADP-dihydrofinasteride adduct — functionally irreversible for the lifetime of that enzyme molecule. This is why tissue DHT suppression outlasts plasma finasteride by 24–48 hours despite a 5–6 hour plasma half-life, and why once-daily (or even EOD) dosing holds serum DHT down at steady state.

At 1 mg/day, you get roughly a 70% drop in serum DHT and a compensatory ~10–15% rise in serum testosterone. Crucially, type I 5αR (dominant in sebaceous glands and non-genital skin) is largely spared, which is why finasteride is milder on sebum and skin oil than dutasteride — and why it also doesn't hit scalp DHT quite as completely.

"Finasteride decreased scalp DHT by 65% and serum DHT by 71% after 42 days compared with baseline." — Drake L, Hordinsky M, Fiedler V, et al., Journal of the American Academy of Dermatology (1999)

Reversal of Follicular Miniaturization#

DHT is the androgen that drives progressive miniaturization of genetically susceptible follicles on the vertex, mid-scalp, and hairline. At the follicle level, DHT binds androgen receptors in the dermal papilla, shortens the anagen (growth) phase, and over successive cycles converts terminal hairs into shorter, finer, depigmented vellus hairs. Occipital (donor) follicles are androgen-insensitive — which is why hair transplants take — and finasteride does nothing for them or against them.

By dropping scalp DHT by ~55–65%, finasteride removes the primary driver of that miniaturization cascade. Susceptible follicles that are still cycling can revert toward terminal morphology; follicles that have fully involuted will not come back. Retention is the real endpoint, regrowth is the bonus — and this is why starting earlier beats starting later.

"Finasteride 1 mg/day slowed the progression of hair loss and increased hair growth in men with androgenetic alopecia." — Kaufman KD, Olsen EA, Whiting D, et al., Journal of the American Academy of Dermatology (1998)

Long-term data confirms the effect holds as long as the drug is on board:

"The therapeutic effect on hair loss was sustained over 5 years, with continued hair preservation and a favorable safety profile." — Kaufman KD, Dawber RP., European Journal of Dermatology (2002)

Stop the drug, and scalp DHT normalizes within weeks — visible loss of gains follows over ~12 months. Treat it like TRT: indefinite commitment or don't start.

The Topical vs Oral Trade-Off#

Topical finasteride (typically a 0.25% solution, ~1 mL/day) exploits the fact that 5αR inhibition is a local-tissue phenomenon. Applied to scalp, it delivers enough drug into dermal papilla to inhibit follicular 5αR while reducing systemic exposure — producing comparable scalp DHT suppression with roughly 20% less serum DHT drop. For sides-sensitive users, this is the rational alternative.

"Topical finasteride demonstrated comparable scalp efficacy to oral finasteride, with lower incidence of adverse effects related to systemic exposure." — Piraccini BM, Blume-Peytavi U, Scarci F, et al., Journal of the European Academy of Dermatology and Venereology (2022)

Important caveat: topical is not zero-systemic. Some drug gets absorbed, some serum DHT suppression occurs, and pregnant partners still can't handle the solution. If you're actively trying to conceive, pause entirely for 3 months — topical or oral, the semen-parameter signal applies to both.

Neurosteroid Suppression (The PFS Pathway)#

5α-reductase doesn't only reduce testosterone to DHT. It also converts progesterone to allopregnanolone and deoxycorticosterone to THDOC — neurosteroids that act as potent positive allosteric modulators of GABA-A receptors. Inhibiting 5αR therefore blunts central GABAergic tone, and this is the current best mechanistic hypothesis for the mood, anxiety, and sexual components of post-finasteride syndrome (PFS) that persist in a minority of users after discontinuation.

"Post-finasteride syndrome describes persistent sexual, neurological, and physical adverse effects that continue after medication discontinuation." — Diviccaro S, Melcangi RC, Giatti S., Neurobiology of Stress (2020)

True PFS incidence is almost certainly well under 1%, but it's real enough that multiple regulatory agencies required label updates. Risk doesn't scale cleanly with dose or duration — which is why going above 1 mg/day buys you no extra scalp protection but does stack extra CNS exposure. If sexual or cognitive sides develop and don't resolve within a few weeks of dose reduction, stop. Don't push through.

Why Finasteride Fails Against Certain AAS#

The mechanism also tells you exactly where finasteride is useless on cycle — and this matters for anyone planning to run gear.

DHT-derived AAS (trenbolone, masteron, proviron, primo, winstrol, anavar, DHB) do not require 5α-reduction to act at the scalp. They bind AR directly. Blocking 5αR does nothing to them. This is the hard mechanistic reason topical AR antagonists — RU58841, pyrilutamide, clascoterone — exist and matter: they compete at the receptor itself, downstream of whatever androgen is driving the follicle.

19-nor compounds (nandrolone/deca, trestolone) are worse. Nandrolone is converted by 5αR into dihydronandrolone (DHN), which is less androgenic at scalp than parent nandrolone. Inhibiting 5αR with finasteride therefore increases scalp androgen exposure on deca and accelerates loss. Finasteride + nandrolone is mechanistically backwards — drop the fin or drop the deca, but don't stack them thinking you're protected.

For a test-only or test + aromatizable cycle, 1 mg/day oral fin is solid. For anything DHT-derived or 19-nor, the scalp protection has to come from topical AR antagonists and oral minoxidil — not from more finasteride.

Common (most users)#

• Initial shed (weeks 2–12) — DHT withdrawal synchronizes follicles into telogen before the anagen rebound. This is a sign the drug is working, not failing. Do not judge results before month 9, and don't bail at month 3 like most quitters do.
• Mild libido dip — reported in ~1.8% of users vs 1.3% on placebo in the Kaufman trials. Usually resolves within 4–8 weeks as the HPG axis recalibrates. If it doesn't settle, drop to 1.25 mg EOD or switch to topical 0.25%.
• Reduced ejaculate volume — ~1.2% incidence, largely cosmetic. No fertility implication on its own. Bumping zinc (25–50 mg/day) and hydration helps some users; otherwise ignore it.
• Softer morning erections / slower refractory — subtle and dose-dependent. Low-dose tadalafil (2.5–5 mg daily) handles this cleanly and stacks well with hair-focused protocols anyway for scalp microcirculation.
• PSA suppression (~50%) — not a side effect so much as a lab artifact. If you're over 40 and getting screened, tell whoever reads the number to double it.

Uncommon (dose-dependent or individual)#

• Persistent erectile dysfunction — ~1.3% vs 0.7% placebo. If still present at week 8, drop to EOD or pivot to topical 0.25%. Check bloodwork: total T, free T, E2, prolactin, SHBG. On cycle, ED is more often an E2 problem than a fin problem — rule that out first.
• Low mood, flat affect, anhedonia — plausibly tied to reduced 5α-reduced neurosteroids (allopregnanolone, THDOC) on GABA-A receptors (Diviccaro 2020). If mood changes within the first few months, don't power through — drop the dose or switch to topical. Prior depression history is a genuine risk flag.
• Gynecomastia — rare at 1 mg, more common at 5 mg BPH dosing. The ~10–15% rise in serum testosterone can push E2 up in aromatase-prone users. If nipple tenderness develops off-cycle, check E2 and consider a low-dose AI or drop to topical.
• Reduced sperm count / motility — modest but real, reversible within ~3 months of cessation. Check a semen analysis if you're planning conception in the next 6–12 months.
• Testicular ache / mild volume change — uncommon, usually self-resolves. Persistent discomfort warrants bloodwork and a dose reduction.

Rare but serious#

• Post-finasteride syndrome (PFS) — persistent sexual, neurological, and physical symptoms continuing after discontinuation. True incidence is unknown but almost certainly well under 1%; the mechanism involves neurosteroid disruption, possible AR hypersensitivity, and epigenetic changes at the androgen receptor.

"Post-finasteride syndrome describes persistent sexual, neurological, and physical adverse effects that continue after medication discontinuation." — Diviccaro et al., Neurobiology of Stress (2020)

Warning signs: sexual or cognitive side effects that fail to resolve within 4–8 weeks of dose reduction, worsening anhedonia, genital numbness. Stop immediately and don't restart. Risk does not scale cleanly with dose or duration, which is why low-dose and topical protocols are the sensible hedge for anyone concerned.

• Severe depression / suicidal ideation — flagged on MHRA and Swedish MPA labels. Rare but the signal is strong enough to take seriously. Prior depressive episodes are a hard entry flag — use topical or skip.
• High-grade prostate cancer signal — the PCPT trial showed a small increase in high-grade tumor detection on finasteride, though total prostate cancer incidence dropped. Most oncologists now attribute this to detection bias. Relevant only if you have a significant family history.
• Male breast cancer — isolated case reports. Discontinue if persistent gynecomastia, nipple discharge, or a unilateral lump develops.

Hard contraindications#

• Pregnancy / women of childbearing potential handling crushed or broken tablets. Finasteride is Category X — teratogenic, disrupts external genital development in male fetuses. Pregnant partners do not handle broken tablets, period.
• Planned near-term conception. Pause oral finasteride a minimum of 3 months before actively trying. Semen parameters recover in that window.
• History of breast cancer or unexplained breast changes — do not initiate.
• Active depression or prior suicidal ideation — pick a topical entry or skip entirely. This is where the PFS risk concentrates.
• Nandrolone / deca / trestolone cycles. Finasteride blocks conversion of nandrolone to the less androgenic dihydronandrolone at the scalp, which means it raises scalp androgen exposure and accelerates hair loss. This is the opposite of what you want. Drop fin on 19-nor cycles and lean on topical AR antagonists (RU58841, pyrilutamide, clascoterone) plus oral minoxidil.
• DHT-derived AAS (tren, masteron, primo, winstrol, anavar, proviron, DHB). Not a safety contraindication — a utility one. Finasteride does nothing useful against these, because they act directly on AR without needing 5α-reduction. Running fin here gives you sides with zero scalp benefit.

Gender and fertility considerations#

Women: contraindicated in women of childbearing potential. Some post-menopausal women use it off-label for female pattern hair loss, but this is outside standard protocol and not what this page is for. Women on AAS who need hair protection should look to spironolactone and topical AR antagonists instead.

Fertility: finasteride modestly reduces sperm count and motility in a subset of men, reversible within ~3 months of cessation. If conception is anywhere on your 6–12 month horizon, pause oral finasteride and bridge with topical 0.25% or drop the drug entirely. Semen analysis at baseline and pre-conception is cheap insurance.

PCT: none required. Finasteride does not suppress the HPTA — if anything, serum testosterone rises slightly ~10–15% on therapy. You can stop cold at any point; hair gains reverse within ~12 months of discontinuation, so treat it like TRT — you're on it indefinitely or you aren't.